{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:19:42Z","timestamp":1787692782496,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinthera.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:55:52Z","timestamp":1787691352000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Manufacturing Complexity and Scale-Up: Hidden Contributors to Drug Safety Risk"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5772-9720","authenticated-orcid":false,"given":"Eric","family":"Hacherl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.08.002_bib0001","series-title":"Guidance for Industry: Exposure-Response Relationships\u2014Study Design, Data Analysis, and Regulatory Applications","year":"2003"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/10543406.2013.735761","article-title":"Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison models","volume":"23","author":"Fu","year":"2013","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0004","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0006","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System. Step 4 version. June 4, 2008. https:\/\/database.ich.org\/sites\/default\/files\/Q10%20Guideline.pdf. Accessed March 26, 2026."},{"key":"10.1016\/j.clinthera.2026.08.002_bib0007","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Guideline Q9(R1): Quality Risk Management. Step 4 version. 18 January 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q9r1-quality-risk-management. Accessed March 25, 2026."},{"key":"10.1016\/j.clinthera.2026.08.002_bib0008","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH harmonised tripartite guideline Q5E: comparability of biotechnological\/biological products subject to changes in their manufacturing process. Step 4. November 18, 2004. https:\/\/database.ich.org\/sites\/default\/files\/Q5E%20Guideline.pdf. Accessed March 26, 2026."},{"key":"10.1016\/j.clinthera.2026.08.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/20420986211038436","article-title":"Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance","volume":"12","author":"Sardella","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0010","series-title":"FDA Pharmaceutical Quality Symposium","article-title":"Pharmaceutical quality in the 21st century: PAT\u2014a framework for innovative pharmaceutical development, manufacturing and quality assurance","author":"Ceragioli","year":"2012"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0011","series-title":"PAT \u2014 A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance","year":"2004"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0012","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1126\/science.abc9588","article-title":"Knowledge transfer for large-scale vaccine manufacturing","volume":"369","author":"Price","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0013","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/bmj.320.7237.768","article-title":"Human error: models and management","volume":"320","author":"Reason","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0014","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0016","first-page":"22","article-title":"Variability of biologics and its impact on biosimilar development","volume":"4","author":"Cornes","year":"2019","journal-title":"EMJ"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0017","series-title":"Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing\u2014Current Good Manufacturing Practice","year":"2004"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0018","series-title":"Angiotensin-II-Receptor Antagonists (Sartans) Containing a Tetrazole Group\u2014Article 31 Referral\u2014CHMP Assessment Report","year":"2021"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0019","article-title":"Understanding the molecular-pharmaceutical basis of sartan recalls focusing on valsartan","volume":"2020","author":"Ray","year":"2020","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0020","series-title":"FDA updates and press announcements on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan, and irbesartan","year":"2018"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0021","series-title":"SEED. Manufacturing Scale-Up of Drugs and Biologics","year":"2024"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0022","series-title":"SEED. Regulatory Knowledge Guide for Biological Products","year":"2023"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0023","series-title":"SEED. Regulatory Knowledge Guide for Cell and Gene Therapies","year":"2023"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0024","series-title":"SEED. Regulatory Knowledge Guide for Small Molecules","year":"2024"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0025","series-title":"ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development","year":"2009"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0026","series-title":"Biotechnology Entrepreneurship","first-page":"447","article-title":"The biomanufacturing of biotechnology products","author":"Conner","year":"2020"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0027","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cite.201100017","article-title":"Process development and design of downstream processes","volume":"83","author":"Strube","year":"2011","journal-title":"Chem Ing Tech"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0028","first-page":"30","article-title":"Best practice tech transfer methods for CGTs","volume":"36","author":"Hewitt","year":"2023","journal-title":"BioPharm Int"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0029","series-title":"SUPAC IR: Immediate Release Solid Oral Dosage Forms: Scale Up and Post Approval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation","year":"1995"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0030","series-title":"Sample sizes for decision making in new manufacturing paradigms: focus area blend uniformity [presentation]. PQRI Workshop on Sample Sizes for Decision Making in New Manufacturing Paradigms","author":"Muzzio","year":"2011"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0031","first-page":"22","article-title":"Lessons in bioreactor scale-up: part 1 \u2013 exploring introductory principles","volume":"22","author":"Chaudhry","year":"2024","journal-title":"BioProcess Int"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ces.2022.118323","article-title":"Mixing and mass transfer in production scale mammalian cell culture reactor using coupled CFD\u2013species transport\u2013PBM validation","volume":"267","author":"Mishra","year":"2023","journal-title":"Chem Eng Sci"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0033","series-title":"Warning Letter to Mylan Pharmaceuticals Inc. (ref. 557903)","year":"2018"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0034","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/pharmaceutics13111909","article-title":"Blend segregation in tablets manufacturing and its effect on drug content uniformity\u2014a review","volume":"13","author":"Jakubowska","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11 Suppl","key":"10.1016\/j.clinthera.2026.08.002_bib0035","first-page":"4","article-title":"Multiproduct facility design and control for biologics","volume":"10","author":"Chi","year":"2012","journal-title":"BioProcess Int"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0036","author":"Dunleavy"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0037","author":"LaFraniere"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0038","author":"Wechsler"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0039","first-page":"12","article-title":"Bridging analytical methods for release and stability testing: technical, quality and regulatory considerations","volume":"14","author":"Ritter","year":"2016","journal-title":"BioProcess Int"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40259-021-00488-5","article-title":"Comparability of biologics: global principles, evidentiary consistency and unrealized reliance","volume":"35","author":"Webster","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0041","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1208\/s12249-014-0087-x","article-title":"Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm","volume":"15","author":"Van Buskirk","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103993","article-title":"A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023","volume":"29","author":"Patel","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clinthera.2026.08.002_bib0043","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH guideline Q14: analytical procedure development. Step 5, Revision 1. November 1, 2023. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q14_Guideline_Step5_Rev1.pdf. Accessed July 21, 2026."},{"key":"10.1016\/j.clinthera.2026.08.002_bib0044","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH guideline Q2(R2): validation of analytical procedures. Step 5. November 1, 2023. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2R2_Guideline_Step5.pdf. Accessed July 21, 2026."},{"key":"10.1016\/j.clinthera.2026.08.002_bib0045","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH guideline E2C(R2): periodic benefit-risk evaluation report (PBRER). Step 5. December 17, 2012. https:\/\/database.ich.org\/sites\/default\/files\/E2C_R2_Guideline.pdf. Accessed July 21, 2026."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:55:56Z","timestamp":1787691356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S0149291826002833"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manufacturing Complexity and Scale-Up: Hidden Contributors to Drug Safety Risk","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}